Companies › L & L Bio Co., Ltd., Ningbo, China
2 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| LB1410 anti-PD-1 and anti-TIM-3 bispecific antibody | PDCD1, HAVCR2 | Phase 1 | Solid Tumor | Dec 2026 |
| LB4330 anti-claudin18.2/IL-10 fusion protein | CLDN18, IL10 | Phase 1 | Solid Tumor | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05357651 | LB1410 | Phase 1 | Solid Tumor | Oncology | Dec 2026 |
| NCT06468358 | LB1410 | Phase 1 | Solid Tumor | Oncology | Dec 2026 |
| NCT06468358 | LB4330 | Phase 1 | Solid Tumor | Oncology | Dec 2026 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.